Prognostic implication of labeling index versus estrogen receptors and tumor size in node-negative breast cancer

Rosella Silvestrini(Fondazione IRCCS Istituto Nazionale dei Tumori), Maria Grazia Daidone(Fondazione IRCCS Istituto Nazionale dei Tumori), G. Di Fronzo(Fondazione IRCCS Istituto Nazionale dei Tumori), Alberto Morabito(Fondazione IRCCS Istituto Nazionale dei Tumori), Pinuccia Valagussa(Fondazione IRCCS Istituto Nazionale dei Tumori), Gianni Bonadonna(Fondazione IRCCS Istituto Nazionale dei Tumori)

Breast Cancer Research and Treatment

October 1, 1986

10.1007/bf01806246

Cited by 132

Abstract

Related Papers

THE ATTRACTIONS OF PROTEINS FOR SMALL MOLECULES AND IONS

George Scatchard|Annals of the New York Academy of Sciences|1949|19.9k

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples

Richard Peto, M. C. Pike, P. Armitage et al.|British Journal of Cancer|1977|8.4k

Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update

Bernard Fisher, Madeline Bauer, D. Lawrence Wickerham et al.|Cancer|1983|1k

The value of estrogen and progesterone receptors in the treatment of breast cancer

C. Kent Osborne, Michael G. Yochmowitz, William A. Knight et al.|Cancer|1980|725

Cancer of the breast: Size of neoplasm and prognosis

Bernard Fisher, Nelson H. Slack, Irwin D. F. Bross et al.|Cancer|1969|486